

Vasoactive Intestinal Peptide Induces S α /S μ Switch Circular DNA in Human B Cells

Shigeharu Fujieda,*[†] James A. Waschek,^{‡§} Ke Zhang,* and Andrew Saxon*^{§||}

*The Hart and Louise Lyon Laboratory, Division of Clinical Immunology/Allergy, Department of Medicine, UCLA School of Medicine, Los Angeles, California; [‡]Department of Psychiatry and Mental Retardation Research Center, UCLA School of Medicine, Los Angeles, California;

[§]The Jonsson Comprehensive Cancer Center Institute, UCLA School of Medicine, Los Angeles, California; ^{||}The Molecular Biology Institute, UCLA School of Medicine, Los Angeles, California; and [†]Department of Otorhinolaryngology, Fukui Medical School, Japan

Abstract

Vasoactive intestinal peptide (VIP), a major neurotransmitter of peripheral nerves, has been suggested to function in host defense by regulating local human immune function. Indirect evidence has been marshaled that VIP can function as a switch factor for IgA in human Ig isotype recombination. In this study we directly tested the ability of VIP to function as a factor driving human B cells into IgA producing cells by assessing its ability to induce switch circular DNA representing direct μ to α switching. In addition we determined the generation of α germ-line transcripts and measured the level of IgA protein produced. Stimulation with VIP and CD40 mAb induced IgA production by human IgD⁺ B cells while VIP or CD40 alone failed to do so. Stimulation of purified IgD⁺ B cells with VIP plus CD40 mAb induced generation of switch circular DNA representing in vitro driven isotype switching from μ to α . CD40 mAb alone induced α germ-line transcripts but not IgA switch circles. Thus VIP, a neurogenic factor, can induce α -specific switching in CD40-activated human B cells and may thereby play an important role in directing the humoral immune response at mucosal surfaces. (*J. Clin. Invest.* 1996; 98:1527–1532.) Key words: vasoactive intestinal peptide • switch circular DNA • α germ-line transcript • IgA isotype switching • transforming growth factor- β

Introduction

Immunoglobulin (Ig) isotype switching is the process whereby B cells initially expressing IgM and/or IgD on their surface switch to other Ig heavy chain loci and thereby provide antibodies with different effector functions but the same antigen specificity (1, 2). Molecular analyses of Ig isotype switching support a model of alignment of two switch region sequences which are 5' to each heavy chain region followed by looping

out and deletion of the intervening DNA (3). Such excised switch circular DNA has been directly demonstrated in murine (4–8) and human B cells (9, 10). Definitive proof of the ability of a signal to function as an isotype switch factor requires demonstration of its ability to induce the appropriate deleted switch circular DNA.

TGF- β has been established as a true switch factor for IgA in murine (11) and human systems (12, 13). However, the role of TGF- β in mucosal-associated lymphoid tissue with its high level of IgA production and the large number of IgA-committed B cells is unknown. Low molecular weight B cell growth factor, derived from the supernatant of PHA-activated T cells, also induces IgA production in PWM-stimulated human B cells by a mechanism that apparently does not involve TGF- β , but otherwise this activity is not characterized (14).

Vasoactive intestinal peptide (VIP),¹ a major neuropeptide of the central and peripheral nervous system, has been shown to induce IgA production by human IgA⁺ B cells (15), fetal B cells, pre-B cells (16), and lamina propria mononuclear cells (17). These findings suggested that VIP might function as a role of switch factor for IgA. To directly test this hypothesis, we tested purified human IgD⁺ B cells for their response to VIP. In the presence of CD40 mAb-driven α germ-line transcripts, VIP induced S α /S μ switch circular DNA, providing direct evidence of VIP-driven μ to α switching and demonstrating that it functions as an IgA switch factor for human B cells.

Methods

Reagents. CD40 mAb, G28-5, was a gift from Dr. E.A. Clark (University of Washington, Seattle, WA). Mouse (IgG) anti-human IgD mAb was made from the δ TA4-1 hybrid cell line obtained from American Type Culture Collection (ATCC HB70, Rockville, MD). VIP and somatostatin (SOM) were purchased from Sigma Chemical Co. (St. Louis, MO).

Cells and cell cultures. Human B cells were isolated from fresh human tonsil as described previously (9, 10). Purified B cell consisted of > 95% CD19⁺ cells and < 1% CD3⁺ cells (10, 18). Resting B cells (IgD⁺ B cell) were positively isolated by anti-human IgD mouse mAb and goat anti-mouse IgG coated magnetic beads (Dynal, Great Neck, NY) (10). This enriched population consisted of 95% IgD⁺ B cells and 4% IgD[−] B cells. IgD⁺ B cells (1×10^6 cells/ml) were cultured in RPMI supplemented with 2 mM of glutamine, 10% FCS, 100 U/ml of penicillin, and 100 μ g/ml of streptomycin. The stimulated cells were harvested for isolation of circular DNA on day 7 and extraction

Address correspondence to Shigeharu Fujieda, M.D., Department of Otorhinolaryngology, Fukui Medical School, Shimoaizuki, Matsuoka, Yoshida, Fukui, 910-11, Japan. Phone: 776-61-3111x2398; FAX: 776-61-8118.

Received for publication 17 May 1996 and accepted in revised form 30 July 1996.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/96/10/1527/06 \$2.00

Volume 98, Number 7, October 1996, 1527–1532

1. Abbreviations used in this paper: SOM, somatostatin; VIP, vasoactive intestinal peptide.

of RNA on day 5, which should be optimal for generation of switch circular DNA and for expression of germ-line transcripts (9, 10).

Ig measurements. Total immunoglobulin levels were measured by ELISA as described previously in the supernatant of cells cultured for 10 d (18, 19).

Isolation of circular DNA. Circular DNA was prepared from the alkaline lysate of total cultured cells (1×10^7 cells) as described previously (9, 10, 20). The precipitated circular DNA was digested with EcoRI to linearize circular DNA and treated with RNase for 2 h at 37°C to remove RNA. The S μ , S α 1, and S α 2 regions have no EcoRI sites. The EcoRI-linearized circular DNA provides for far superior amplification compared with undigested supercoiled DNA (9). After linearization, the treated circular DNA was used as PCR templates.

RNA extraction and reverse transcription. Total mRNA was obtained from cultured B cells (1×10^7 cells) using Trizol reagent (Life Technologies, Gaithersburg, MD) (21) and then digested with DNase I (Sigma) to remove contaminating DNA. 2 μ g of total RNA was reverse-transcribed to cDNA using oligo (dT)₁₅ (Boehringer-Mannheim Co., Indianapolis, IN) as primer and mouse Moloney leukemia virus reverse transcriptase (Life Technologies).

PCR strategy. Nested primer PCR runs for switch fragments were performed on prepared circular DNA as described before (9, 10). Briefly, PCR was run in a 50 μ l/reaction with 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 1.5 mM MgCl₂, 5% DMSO, 50 pmol primer/reaction, and 2.5 U of *Taq* polymerase. The PCR assays were carried out as 1 min denature (94°C), 1 min annealing (65°C on the first PCR, 68°C on the second PCR), and 2 min extension (72°C) for 40 cycles. The primer sequences are as follows: first round PCR: A1, ACAGCAGCCCTCTTGGCAGGCA, and M1, GGTGAGTGTGATGGGGAA-CGCAGTGTA; second round PCR: A2, CGTGAGGGTGGACCTGCCATGA, and M2, CCATCTATGTCCAACAAGATCATGA.

The μ primers (M1 and M2) are located 3' from the end of S μ (22) and the α primers (A1 and A2) are located in the I α region (23, 24), which is just 5' to the S α sequence. The PCR assay for α germ-line transcripts was carried out at 94°C for 1 min, 65°C for 1 min, and 72°C for 1 min for 40 cycles. The primers were A1 (above) and C α 1, CGTGAGGTTTCGCTTCTGAACCTAAGAG (25, 26).

Cloning and screening. The PCR products of switch circular DNA were cloned by TA cloning (Invitrogen, San Diego, CA). Positive clones were selected by hybridization with an S μ probe labeled with [³²P]dCTP by random priming (10). Hybridization was conducted according to the standard methods with hybridization in 50% formamide performed at 42°C and the washing temperature for blots at 68°C.

DNA sequencing. Nucleotide sequences were determined by the standard dideoxyl chain termination method using a DNA sequencing kit (Sequenase version 2.0; Amersham, Arlington Heights, IL).

Results and Discussion

VIP induced IgA production by IgD⁺ B cells. Highly purified IgD⁺ B cells were cultured with various concentrations of VIP in the presence of CD40 mAb (0.1 μ g/ml) for 10 d, and the IgA level in the supernatant was measured by ELISA (Fig. 1). Stimulation of IgD⁺ B cells with VIP ($\geq 10^{-10}$ M) plus CD40 mAb significantly enhanced IgA production in four of four experiments. Stimulation with VIP or CD40 alone had no effect on IgA levels. VIP plus CD40 mAb did not enhance IgG and IgE production from IgD⁺ B cells (data not shown). Concentrations of SOM ranging from 10^{-12} to 10^{-6} M were used with CD40 mAb but failed to induce IgA production by IgD⁺ B cells (data not shown).

The combination of TGF- β , IL-10, and CD40 mAb has been shown to induce the greatest IgA production from human IgD⁺ B cells (12). Indeed, in our experiments, IgA production driven by optimal concentrations of TGF- β 1 (1 ng/ml)

plus IL-10 (500 U/ml) plus CD40 mAb was about two times higher than IgA production driven by VIP (10^{-10} M) plus IL-10 plus CD40 mAb stimulation (24.7 ± 3.3 ng/ml vs. 12.4 ± 1.8 ng/ml, respectively, $P < 0.01$). However, in the absence of IL-10, VIP (10^{-10} M) plus CD40 mAb stimulation produced 7.4 ± 2.4 ng/ml of IgA while TGF- β 1 (1 ng/ml) plus CD40 mAb failed to induce IgA production (0.6 ± 0.4 ng/ml). Anti-TGF- β Ab (10 μ g/ml) failed to block IgA production induced by VIP plus CD40 mAb, further showing that TGF- β did not mediate the effects of VIP (data not shown). The addition of VIP antagonist, VIP-[Ac-Tyr1, D-phe]-GRF(1-29) amide (10^{-8} M, Sigma), to the culture medium blocked the IgA induction by VIP plus CD40 mAb (< 0.01 ng/ml), while the SOM antagonist, aminoheptanoyl-phe-D-Trp-Lys-O-Benzyl-Thr (10^{-8} M, Sigma), did not (data not shown). The data of neutralization test at the protein level are in agreement with previous findings of IgA production from IgA⁻ B cells (15).

Induction of α germ-line transcripts in IgD⁺ B cells. Ig isotype switching is preceded by germ-line transcription from the targeted heavy chain locus (27, 28). The importance of germ-line transcripts in isotype switching has been confirmed recently by gene targeting experiments (29–33). However the exact role of germ-line transcripts/transcription remains controversial as does the requirement for specific I, switch, or constant region sequences (34). The presence of α subclass germ-line transcripts was assessed here by using an RT-PCR strategy.

As shown in Fig. 2 A, CD40 mAb stimulation (0.1 μ g/ml) alone reproducibly induced α germ-line transcripts in IgD⁺ B cells in all four experiments with independent tonsil cells. The amplified fragments for α germ-line transcripts were cloned and identified as α germ-line transcripts by DNA sequence analysis (data not shown). On the other hand, stimulation with VIP (10^{-9} M) alone induced α germ-line transcripts in two out of four experiments (50%). Presently, it remains unclear




Figure 1. VIP plus CD40 mAb stimulation induces IgA production by IgD⁺ B cells. Purified IgD⁺ B cells (1×10^6 cells/ml) were cultured with medium or CD40 mAb (0.1 μ g/ml) in the presence of various concentration of VIP as shown. Supernatants were harvested for IgA determination on day 10 of culture. The results were expressed as mean \pm SD of triplicate cultures (one out of four experiments shown). **Significant difference in the IgA production versus nonstimulated cells ($P < 0.01$).

whether VIP alone can truly and reproducibly induce α germ-line transcript since its ability in this regard appears to depend on the response of the specific cell donor. However, in individual donors, there was definitely no relationship between this VIP-induced expression of α germ-line transcripts and subsequent levels of IgA production driven by VIP plus CD40 mAb. To estimate the sensitivity of our PCR assay for α germ-line transcripts, plasmid DNA containing a $I\alpha$ -C α fragment (α germ-line transcripts) were serially diluted and subjected to PCR amplification (Fig. 2 B). The sensitivity was determined for 10^5 copies of template per reaction (0.18 pg, cDNA amount per reaction). Control unstimulated IgD⁺ B cells showed no expression of α germ-line transcripts as expected. As a positive control for α germ-line transcripts, we used the PCR amplified band from IgD⁺ B cells stimulated with TGF- β 1 (1 ng/ml) (26). Semiquantitative analysis by the comparison shown in Fig. 2 B demonstrated that TGF- β alone induced severalfold more α germ-line transcripts than VIP plus CD40 mAb stimulation.

VIP and CD40 mAb stimulation induced switching from μ to α as determined by switch circle analysis. Gel electrophoresis of nested PCR products from purified IgD⁺ B cells stimulated with VIP (10^{-9} M) plus CD40 mAb (0.1 μ g/ml) showed amplification of multiple circular DNA fragments (Fig. 3). These multiple bands hybridized on Southern blot with a 3' S μ probe, suggesting that amplified fragments represent S α /S μ switch circular DNA. Such bands were not detected after B cell stimulation with VIP alone, CD40 mAb alone, or SOM

(10^{-9} M) plus CD40 mAb in four independent experiments with four individual sets of tonsil. The sensitivity of this nested PCR assay for detection of switch circular DNA was assessed using a cloned plasmid containing S α /S μ fragment. This plasmid was serially diluted and then used as a template for nested PCR assay. As shown in Fig. 3 C, our PCR assay could amplify between 1 and 10 copies of template (1.9×10^{-6} pg, DNA amount per reaction).

PCR products from VIP plus CD40 mAb-stimulated B cells were cloned by a TA cloning and six clones were isolated




Figure 2. (A) Induction of α germ-line transcripts in IgD⁺ B cells as assessed by RT-PCR assay. Purified IgD⁺ B cells were cultured for 5 d with medium, CD40 mAb (0.1 μ g/ml) alone, VIP (10^{-9} M) alone, VIP plus CD40 mAb, or TGF- β 1 (1 ng/ml) alone. Cells stimulated with CD40 mAb, VIP plus CD40 mAb, and TGF- β expressed the predicted 545-bp band for α germ-line transcripts. The lane on the far left is a 123-bp DNA ladder. (B) Sensitivity of the PCR assay for α germ-line transcripts. A plasmid containing $I\alpha$ -C α fragment was diluted and amplified. 1 gram of this plasmid is equivalent to 5.5×10^{17} copies of template.




Figure 3. Identification of PCR products representing S α /S μ switch circular DNA. (A) Agarose gel electrophoresis of PCR-amplified switch circle fragments derived from various cells. Purified IgD⁺ B cells were cultured for 7 d with medium alone, CD40 mAb (0.1 μ g/ml) alone, VIP (10^{-9} M) alone, VIP plus CD40 mAb, or SOM (10^{-9} M) plus CD40 mAb. Multiple bands were seen in only the fourth lane derived from cells stimulated with VIP plus CD40 mAb. (B) Southern blot analysis of PCR products shown in A. The sample was transferred to a nylon membrane and hybridized with S μ probe. Multiple positive bands were seen in the fourth lane. These were shown to be chimeric S α /S μ fragments by sequencing as shown in Fig. 4. (C) Sensitivity of the nested PCR for the detection of switch circular DNA. A plasmid containing S α /S μ switch fragment was serially diluted and amplified. 1 gram of this plasmid is equivalent to 5.2×10^{17} copies of template.

and sequenced. Since the human $\alpha 1$ and $\alpha 2$ regions are highly homologous (23, 24), we were unable to determine the α -subclass of the α fragment in the cloned α/μ PCR products. The structure of all six clones showed they represented direct class switching from μ to α (Fig. 4). As expected, no consensus sequence was found at the α/μ breakpoints.

The assay developed in our laboratory for detection of deleted switch circular DNA using the inverted nested PCR technique is not influenced by proliferation or the presence of switched cells. Switch circular DNA does not replicate as episomal DNA (4) and proliferation of cells makes the copy number of circular DNA, in fact, decrease relative to the number of cells. That α/μ switch circular fragments were not amplified by our PCR method used with unstimulated unfractionated tonsil B cells (data not shown) demonstrates the specificity of this method for active switching (9, 10) as this cell population contains cells having already undergone isotype switch to all isotypes.

Comparison between VIP and TGF- β as α switch factor. Our results demonstrate that VIP induces α switch recombination in the presence of CD40 ligation and there was induction of IgA to readily detectable levels in the cultures. Using our nested PCR method, we also amplified α/μ switch circular fragments from B cells stimulated with TGF- β plus CD40 mAb in the absence of IL-10 (data not shown), although no significant IgA protein was detected in the supernatant of IgD⁺ B cells stimulated with TGF- β and CD40 mAb. Defrance et al. (12) proposed that IgA isotype switching occurs after costimulation of IgD⁺ B cells with TGF- β and CD40 mAb, and a subsequent signal, such as IL-10, is necessary for growth and differentiation of the newly IgA-committed B cells. They found that whereas IL-4 and CD40 mAb are sufficient to induce commitment of human B cells to IgE secretion, TGF- β and CD40 mAb consistently failed to elicit IgA synthesis from IgD⁺ B cells (12). This is in agreement with our data.

Thus, although TGF- β appears to be more effective at driving α germ-line transcriptions than VIP, it is not as effective as a switch and differentiation factor when combined solely with CD40 ligation. A quantitative analysis of α switch recombination comparing VIP and TGF- β theoretically could be determined by the digestion circularization PCR (35); a suitable system has not been established in human fresh cells. Furthermore, IL-10 is very readily found in the airways of humans (36) and mucosal switching to IgA in vivo likely occurs in the presence of a variety of concentrations of this cytokine.

VIP as a regulator of the immune response. Neuropeptides and cytokines are primary mediators of the interaction between cells of the nervous and immune systems (37, 38). VIP has been demonstrated to modulate numerous aspects of the immune response in vitro (39, 40). VIP is detected extensively in the postsynaptic parasympathetic innervation and intrinsic neurons in the lamina propria and submucosa of the upper respiratory system, lung, and gut (40–43). These neurons have been shown to directly innervate mucosal lymphoid tissue (44). VIP can alter the function of the lymphocytes via VIP receptors, the presence of which has been reported on human peripheral B and T cells (45, 46). The concentration (1×10^{-9} M) used by us in the induction of switch circular DNA was fully consistent with the effect being mediated by the high-affinity VIP (VIP1) receptor (38, 39, 45, 47, 48). That the VIP1 receptor could mediate this effect is supported by the recent finding that the VIP1 receptor gene is expressed at readily detectable levels in human peripheral blood lymphocytes (49). The level of VIP in nasal secretions of healthy subjects was reported to be ~ 40 times higher than that in plasma (50), while another study showed that both allergen and histamine nasal challenge enhanced the release of VIP, substance P, and the calcitonin gene-related peptide, whereas histamine challenge specifically enhanced VIP release in nasal secretions (51). Levels of $\sim 10^{-11}$ M VIP were measured in very diluted lavage flu-




Figure 4. Nucleotide sequences surrounding the breakpoints in six cloned switch circular DNA fragments from cells stimulated with VIP plus CD40 mAb. The arrows indicate the breakpoint site of $S\alpha 1$ part (top) and $S\mu$ part (bottom). The number of breakpoint site indicates corresponding position of $S\alpha 1$ in reference 23 (clone number: P217-1, P222-19, 23, and 33) or in reference 24 (clone number: P220-12, and P222-34), and of $S\mu$ in reference 22.

ids; the levels at the interface of VIP neurons and lymphoid tissues are likely several logs higher.

VIP release can be brought about by mechanical and chemical stimuli which induce inflammation, e.g., HCl, hypertonic NaCl, and hypertonic glucose, and by antigen-allergen challenge (51–53). Little is known about VIP release in response to early viral or bacterial infection. The ability of the mucosal nervous system to release VIP in a matter of seconds after topical stimulation provides a mechanism by which isotype switching to IgA can be initiated in a far more rapid fashion than possible through the synthesis and release of cytokines. The possible benefit from this is apparent as IgA is the predominant Ig effector molecule of mucosal immunity functioning as the first line of specific immunologic defense against many viral and microbial pathogens (54, 55).

VIP-induced isotype switch is likely to be an important component of a larger immune response orchestrated by VIP, perhaps acting in concert with other neurotransmitters. In this regard, subnanomolar concentrations of VIP have been shown also to alter lymphocyte trafficking in vivo and in vitro and to stimulate the proliferation of cultured lymphocytes (47, 48, 56, 57). VIP also acts upon natural killer cells and macrophages in vitro (58, 59) and protects tissue against a variety of types of inflammatory and other injuries (60, 61). Thus, although it classically acts as a neurotransmitter or neuromodulator, VIP certainly functions as a switch factor for human IgA and likely functions as an important neurogenic mediator of local immune and inflammatory responses.

Acknowledgments

This work was supported by United States Public Health Service grant AI-15251, the UCLA Asthma, Allergy and Immunologic Disease Center (AI-34567) funded by the National Institute of Allergy and Infectious Disease and the National Institute of Environmental Health Science, and gifts from the Clemente Foundation, Sara and Robert LeBien, and the Allergy Research Foundation. Also, this work was supported by a grant-in-aid for encouragement of young scientists from the Ministry of Education, Science, Sports and Culture of Japan.

References

- Esser, C., and A. Radbruch. 1990. Immunoglobulin class switching: molecular and cellular analysis. *Annu. Rev. Immunol.* 8:717–735.
- Yuan, R., A. Casadevall, G. Spira, and M.D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to *Cryptococcus neoformans* into a protective antibody. *J. Immunol.* 154:1810–1816.
- Honjo, T., and T. Kataoka. 1978. Organization of immunoglobulin heavy chain genes and allelic deletion model. *Proc. Natl. Acad. Sci. USA.* 75:2140–2144.
- Schwedler, U.V., H.M. Jack, and M. Wabl. 1990. Circular DNA is a product of the immunoglobulin class switch rearrangement. *Nature (Lond.)* 345:452–456.
- Matsuoka, M., K. Yoshida, T. Maeda, S. Usuda, and H. Sakano. 1990. Switch circular DNA formed in cytokine-treated mouse splenocytes: evidence for intramolecular DNA deletion in immunoglobulin class switch. *Cell* 62:135–142.
- Iwasato, T., A. Shimizu, T. Honjo, and H. Yamagishi. 1990. Circular DNA is excised by immunoglobulin class switch recombination. *Cell* 62:143–149.
- Yoshida, K., M. Matsuoka, S. Usuda, A. Mori, K. Ishizaka, and H. Sakano. 1990. Immunoglobulin switch circular DNA in the mouse infected with *Nippostrongylus brasiliensis*: evidence for successive class switching from μ to ϵ via $\gamma 1$. *Proc. Natl. Acad. Sci. USA.* 87:7829–7833.
- Iwasato, T., H. Arakawa, A. Shimizu, T. Honjo, and H. Yamagishi. 1992. Biased distribution of recombination sites within S regions upon immunoglobulin class switch recombination induced by transforming growth factor β and li-

- popolysaccharide. *J. Exp. Med.* 175:1539–1546.
- Zhang, K., F.C. Mills, and A. Saxon. 1994. Switch circles from IL-4-directed ϵ class switching from human B lymphocytes. Evidence for direct, sequential, and multiple step sequential switch from μ to ϵ Ig heavy chain gene. *J. Immunol.* 152:3427–3435.
- Fujieda, S., K. Zhang, and A. Saxon. 1995. IL-4 plus CD40 monoclonal antibody induces human B cells γ subclass specific isotype switching: switching to $\gamma 1$, $\gamma 3$, and $\gamma 4$, but not $\gamma 2$. *J. Immunol.* 155:2318–2328.
- Lebman, D.A., F.D. Lee, and R.L. Coffman. 1990. Mechanism for transforming growth factor β and IL-2 enhancement of IgA expression in lipopolysaccharide-stimulated B cell cultures. *J. Immunol.* 144:952–957.
- Defrance, T., B. Vanbervliet, F. Brière, I. Durand, F. Rousset, and J. Banchereau. 1992. Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. *J. Exp. Med.* 175:671–682.
- Vlasselaer, P., J. Punnonen, and J.E. Vries. 1992. Transforming growth factor- β directs IgA switching in human B cells. *J. Immunol.* 148:2062–2067.
- Bertolini, J.N., J. Bertolini, E. Thean, and E.M. Benson. 1992. Human low molecular weight B cell growth factor induces surface IgM⁺/A⁺ B cells to express and secrete IgA. *J. Immunol.* 149:1771–1778.
- Kimata, H., and M. Fujimoto. 1994. Vasoactive intestinal peptide specifically induces human IgA1 and IgA2 production. *Eur. J. Immunol.* 24:2262–2265.
- Kimata, H., and M. Fujimoto. 1995. Induction of IgA1 and IgA2 production in immature human fetal B cells and pre-B cells by vasoactive intestinal peptide. *Blood* 85:2098–2104.
- Boirivant, M., S. Fais, B. Annibale, D. Agostini, G.D. Fave, and F. Pallone. 1994. Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin A production by intestinal lamina propria lymphocytes. *Gastroenterology* 106:576–582.
- Zhang, K., E.A. Clark, and A. Saxon. 1991. CD40 stimulation provides an IFN- γ -independent and IL-4-dependent differentiation signal directly to human B cells for IgE production. *J. Immunol.* 146:1836–1842.
- Macy, E., D.M. Kemeny, and A. Saxon. 1988. Enhanced ELISA: how to measure less than 10 picograms of a specific protein (immunoglobulin) in less than 8 hours. *FASEB (Fed. Am. Soc. Exp. Biol.) J.* 2:3003–3010.
- Griffin, B.E., E. Björck, G. Bjursell, and T. Lindahl. 1981. Sequence complexity of circular Epstein-Barr virus DNA in transformed cells. *J. Virol.* 40:11–19.
- Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156–159.
- Mills, F.C., J.S. Brooker, and R.D. Camerini-Otero. 1990. Sequences of human immunoglobulin switch regions: implications for recombination and transcription. *Nucleic Acids Res.* 18:7305–7316.
- Nilsson, L., K.B. Islam, O. Olafsson, I. Zalcberg, C. Samakovlis, L. Hammarström, C.I.E. Smith, and P. Sideras. 1991. Structure of TGF- $\beta 1$ -induced human immunoglobulin C $\alpha 1$ and C $\alpha 2$ germ-line transcripts. *Int. Immunol.* 3:1107–1115.
- Islam, K.B., B. Baskin, L. Nilsson, L. Hammarström, P. Sideras, and C.I.E. Smith. 1994. Molecular analysis of IgA deficiency. Evidence for impaired switching to IgA. *J. Immunol.* 152:1442–1452.
- Flanagan, J.G., M. Lefranc, and T.H. Rabbitts. 1984. Mechanism of divergence and convergence of the human immunoglobulin $\alpha 1$ and $\alpha 2$ constant region gene sequences. *Cell* 36:681–688.
- Kitani, A., and W. Strober. 1994. Differential regulation of C $\alpha 1$ and C $\alpha 2$ germ-line and mature mRNA transcripts in human peripheral blood B cells. *J. Immunol.* 153:1466–1477.
- Stavnezer-Nordgren, J., and S. Sirlin. 1986. Specificity of immunoglobulin heavy chain switch correlates with activity of germline heavy chain genes prior to switching. *EMBO (Eur. Mol. Biol. Organ.) J.* 5:95–102.
- Yancopoulos, G.D., R.A. Depinho, K.A. Zimmerman, S.G. Lutzker, N. Rosenberg, and F.W. Alt. 1986. Secondary genomic rearrangement events in pre-B cells: V_HDJ_H replacement by a LINE-1 sequence and directed class switching. *EMBO (Eur. Mol. Biol. Organ.) J.* 5:3259–3266.
- Jung, S., K. Rajewsky, and A. Radbruch. 1993. Shutdown of class switch recombination by deletion of a switch region control element. *Science (Wash. DC)* 259:984–987.
- Zhang, J., A. Bottaro, S. Li, V. Stewart, and F.W. Alt. 1993. A selective defect in IgG2b switching as a result of targeted mutation of the I $\gamma 2$ b promoter and exon. *EMBO (Eur. Mol. Biol. Organ.) J.* 12:3529–3537.
- Xu, L., B. Gorham, S.C. Li, A. Bottaro, F.W. Alt, and P. Rothman. 1993. Replacement of germ-line ϵ promoter by gene targeting alters control of immunoglobulin heavy chain class switching. *Proc. Natl. Acad. Sci. USA.* 90:3705–3709.
- Bottaro, A., R. Lansford, L. Xu, J. Zhang, P. Rothman, and F.W. Alt. 1994. S region transcription *per se* promotes basal IgE class switch recombination but additional factors regulate the efficiency of the process. *EMBO (Eur. Mol. Biol. Organ.) J.* 13:665–674.
- Lorenz, M., S. Jung, and A. Radbruch. 1995. Switch transcripts in immunoglobulin class switching. *Science (Wash. DC)* 267:1825–1828.
- Harriman, G.R., A. Bradley, S. Das, P.R. Fani, and A.C. Davis. 1996. IgA class switch in I α exon-deficient mice. Role of germline transcription in

class switch recombination. *J. Clin. Invest.* 97:477–485.

35. Chu, C.C., W.E. Paul, and E.E. Max. 1992. Quantitation of immunoglobulin μ - γ 1 heavy chain switch region recombination by a digestion-circularization polymerase chain reaction method. *Proc. Natl. Acad. Sci. USA.* 89:6978–6982.

36. Borish, L., A. Aarons, J. Rumbyrt, P. Cvietusa, J. Negri, and S. Wenzel. 1996. Interleukin-10 regulation in normal subjects and patients with asthma. *J. Allergy Clin. Immunol.* 97:1288–1297.

37. Goetzl, E.J., D.C. Adelman, and S.P. Sreedharan. 1990. Neuroimmunology. *Adv. Immunol.* 48:161–190.

38. Ottaway, C.A., and A.J. Husband. 1992. Central nervous system influences on lymphocyte migration. *Brain Behav. Immun.* 6:97–116.

39. Kimata, H., A. Yoshida, M. Fujimoto, and H. Mikawa. 1993. Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. *J. Immunol.* 150:4630–4640.

40. Xin, Z., H. Tang, and D. Ganea. 1994. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. *J. Neuroimmunol.* 54:59–68.

41. Said, S.I. 1984. Vasoactive intestinal polypeptide (VIP): current status. *Peptides.* 5:143–150.

42. Ueyama, T., K. Kozuki, T. Houtani, M. Ikeda, M. Kitajiri, T. Yamashita, T. Kumazawa, I. Nagatsu, and T. Sugimoto. 1990. Immunolocalization of tyrosine hydroxylase and vasoactive intestinal polypeptide in nerve fibers innervating human palatine tonsil and paratonsillar gland. *Neurosci. Lett.* 116:70–74.

43. Baraniuk, J.N., J.D. Lundgren, M. Okayama, J. Mullol, M. Merida, J.H. Shelhamer, and M.A. Kaliner. 1990. Vasoactive intestinal peptide in human nasal mucosa. *J. Clin. Invest.* 86:825–831.

44. Ottaway, C.A. 1991. Neuroimmunomodulation in the intestinal mucosa. *Gastroenterol. Clin. North Am.* 20:511–529.

45. Danek, A., M.S. O'Dorisio, T.M. O'Dorisio, and J.M. George. 1983. Specific binding sites for vasoactive intestinal polypeptide on nonadherent peripheral blood lymphocytes. *J. Immunol.* 131:1173–1177.

46. Ottaway, C.A., T.E. Lay, and G.R. Greenberg. 1990. High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes. *J. Neuroimmunol.* 29:149–155.

47. Ottaway, C.A. 1987. Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. *Immunology.* 62:291–297.

48. Johnston, J.A., D.D. Taub, A.R. Lloyd, K. Conlon, J.J. Oppenheim, and D.J. Kevlin. 1994. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. *J. Immunol.* 153:1762–1768.

49. Waschek, J.A., D.T. Bravo, and M.L. Richards. 1995. High levels of

VIP/PACAP receptor gene expression in primary and tumor lymphoid cells. *Regul. Pept.* 60:149–157.

50. Chaen, T., N. Watanabe, G. Mogi, K. Mori, and M. Takeyama. 1993. Substance P and vasoactive intestinal peptide in nasal secretions and plasma from patients with nasal allergy. *Ann. Otol. Rhinol. Laryngol.* 102:16–21.

51. Mosimann, B.L., M.V. White, R.J. Hohman, M.S. Goldrich, H.C. Kaulbach, and M.A. Kaliner. 1993. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. *J. Allergy Clin. Immunol.* 92:95–104.

52. Goetzl, E.J., S.P. Sreedharan, and H.B. Kaltrider. 1994. Neuroregulation of pulmonary immunity: the roles of substance P and vasoactive intestinal peptide. In *Neuropeptides in Respiratory Medicine*. M.A. Kaliner, P.J. Barnes, G.H.H. Kunkel, and J.N. Baraniuk, editors. Marcel Dekker, New York. 607–620.

53. Schulzke, J.D., E.D. Riecken, and M. Fromm. 1995. Distension-induced electrogenic Cl^- secretion is mediated via VIP-ergic neurons in rat rectal colon. *Am. J. Physiol.* 268:G725–G731.

54. Kilian, M., J. Mestecky, and M.W. Russell. 1988. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. *Microbiol. Rev.* 52:296–303.

55. Mazanec, M.B., J.G. Nedrud, C.S. Kaetzel, and M.E. Lamm. 1993. A three-tiered view of the role of IgA in mucosal defense. *Immunol. Today.* 14:430–434.

56. Ottaway, C.A. 1984. In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells. *J. Exp. Med.* 160:1054–1069.

57. Bondesson, L., K. Norolind, S. Liden, G. Gafvelin, E. Theodorsson, and V. Mutt. 1991. Dual effects of vasoactive intestinal peptide (VIP) on leucocyte migration. *Acta Physiol. Scand.* 141:477–481.

58. Pleszczynski, M.R., D. Bolduc, and S.S. Pierre. 1985. The effect of vasoactive intestinal peptide on human natural killer cell function. *J. Immunol.* 135:2569–2573.

59. Chedeville, A., L. Mirossay, E. Chastre, I. Hurbain-Kosmath, M. Lopez, and C. Gespach. 1993. Interaction of VIP, PACAP and related peptides in normal and leukemic human monocytes and macrophages. *FEBS Lett.* 319:171–176.

60. Berisha, H., H. Foda, H. Sakakibara, M. Trotz, H. Pakbaz, and S.I. Said. 1990. Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase. *Am. J. Physiol.* 259:L151–L155.

61. Said, S.I. 1991. VIP as a modulator of lung inflammation and airway constriction. *Am. Rev. Respir. Dis.* 143:S22–S24.